Significant progress for patients with sarcoma at #ASCO25 with positive results from 3 phase III trials. Pimicotinib for TGCT, anlotinib for STS and catequentinib for LMS. All are TKIs. @CleClinicMD#CleClinicCancer
Another year starting @bikeVeloSano with @DrJohnSuh! About to start VeloSano 10. Already $4.5 million raised! That’s 100% for innovative #cancer research. VeloSano.org.